Ionis Pharmaceuticals Inc TRYNGOLZ (olezarsen) FDA sHTG Approval Webcast Transcript
Good afternoon and welcome to Ionis' conference call to discuss the FDA approval of TRYNGOLZA for sHTG.
As a reminder: Note that this conference call is being recorded.
At this time, I would like to turn the call over to Wade Walke, Senior Vice President of Investor Relations, to lead off the call. Wade, please begin.
Thank you, Sylvie. Thank you to everyone who has joined us today, as we discussed the FDA approval of TRYNGOLZA for SHTG, which is now approved in the US to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.
Please be sure to visit the Investors section of the Ionis website to see the press release that Ionis issued earlier today, along with the slides accompanying today's webcast.
Before we begin, I would like to remind you that our discussion today will contain forward-looking statements that are based on our current expectations and beliefs. Such statements are subject to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
